Cholinergic anti-inflammatory pathway and COVID-19

[Image: see text] The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehranfard, Danial, Speth, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905591/
https://www.ncbi.nlm.nih.gov/pubmed/35411295
http://dx.doi.org/10.34172/bi.2022.23980
_version_ 1784665220416798720
author Mehranfard, Danial
Speth, Robert C.
author_facet Mehranfard, Danial
Speth, Robert C.
author_sort Mehranfard, Danial
collection PubMed
description [Image: see text] The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.
format Online
Article
Text
id pubmed-8905591
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tabriz University of Medical Sciences (TUOMS Publishing Group)
record_format MEDLINE/PubMed
spelling pubmed-89055912022-04-10 Cholinergic anti-inflammatory pathway and COVID-19 Mehranfard, Danial Speth, Robert C. Bioimpacts Spotlight [Image: see text] The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists. Tabriz University of Medical Sciences (TUOMS Publishing Group) 2022 2022-01-22 /pmc/articles/PMC8905591/ /pubmed/35411295 http://dx.doi.org/10.34172/bi.2022.23980 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc/4.0/ This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Spotlight
Mehranfard, Danial
Speth, Robert C.
Cholinergic anti-inflammatory pathway and COVID-19
title Cholinergic anti-inflammatory pathway and COVID-19
title_full Cholinergic anti-inflammatory pathway and COVID-19
title_fullStr Cholinergic anti-inflammatory pathway and COVID-19
title_full_unstemmed Cholinergic anti-inflammatory pathway and COVID-19
title_short Cholinergic anti-inflammatory pathway and COVID-19
title_sort cholinergic anti-inflammatory pathway and covid-19
topic Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905591/
https://www.ncbi.nlm.nih.gov/pubmed/35411295
http://dx.doi.org/10.34172/bi.2022.23980
work_keys_str_mv AT mehranfarddanial cholinergicantiinflammatorypathwayandcovid19
AT spethrobertc cholinergicantiinflammatorypathwayandcovid19

Ejemplares similares